Lucy Lu's most recent trade in Willis Towers Watson Public Limited Co was a trade of 41 Ordinary Shares, nominal value $0.000304635 per share done . Disclosure was reported to the exchange on July 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2026 | 41 | 22,758 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Bath & Body Works Inc | Lucy O. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,970 | 25,451 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Hertz Global Holdings Inc - Ordinary Shares (New) | Lucy Clark Dougherty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 31,877 | 102,766 (0%) | 0% | 0 | Common Stock | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 14,609 | 0 | - | - | Restricted Stock Units | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Purchase of securities on an exchange or from another person at price $ 263.36 per share. | 06 May 2026 | 1,896 | 22,717 (0%) | 0% | 263.4 | 499,340 | Ordinary Shares, nominal value $0.000304635 per share |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 104,000 | 104,000 | - | - | Common Stock Option | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 1,761 | 21,046 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.29 per share. | 20 Apr 2026 | 225 | 20,821 (0%) | 0% | 298.3 | 67,116 | Ordinary Shares, nominal value $0.000304635 per share |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2026 | 35 | 19,285 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 82,300 | 0 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 82,300 | 82,300 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 73,665 | 73,665 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 73,665 | 0 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 66,000 | 66,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 66,000 | 0 | - | - | Stock Option (right to buy) | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 3,850 | 3,850 | - | - | Stock Option | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 1,305 | 1,305 | - | - | Restricted Stock Units | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2026 | 767 | 1,564 (0%) | 0% | 0 | Ordinary Shares | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2026 | 767 | 1,558 | - | - | Restricted Stock Units | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 367.49 per share. | 25 Feb 2026 | 224 | 1,340 (0%) | 0% | 367.5 | 82,318 | Ordinary Shares |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 77,000 | 77,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 38,000 | 118,363 | - | 0 | Common Stock | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Purchase of securities on an exchange or from another person at price $ 284.84 per share. | 13 Feb 2026 | 3,500 | 19,250 (0%) | 0% | 284.8 | 996,929 | Ordinary Shares, nominal value $0.000304635 per share |
| SAB Biotherapeutics Inc | Lucy To | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 2,400,000 | 2,400,000 | - | - | Stock option (right to buy) | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 1,151 | 2,339 | - | - | Restricted Stock Units | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 1,151 | 1,151 (0%) | 0% | 0 | Ordinary Shares | |
| Eaton | Lucy Clark Dougherty | See Remarks below. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 360.27 per share. | 03 Feb 2026 | 354 | 797 (0%) | 0% | 360.3 | 127,536 | Ordinary Shares |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 30 | 15,750 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 05 Jan 2026 | 5,512 | 75,363 | - | 1.0 | 5,578 | Common Stock |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.00 per share. | 05 Jan 2026 | 3,295 | 80,875 | - | 1.0 | 3,305 | Common Stock |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 39,894 | 39,894 | - | - | Restricted Stock Unit | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 21,552 | 72,311 (0%) | 0% | - | Common Stock | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 21,552 | 0 | - | - | Restricted Stock Unit | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 16.15 per share. | 26 Dec 2025 | 148 | 7,680 (0%) | 0% | 16.1 | 2,390 | Common Stock |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2025 | 4,000 | 4,000 | - | - | Common Stock Option | |
| Bath & Body Works Inc | Lucy O. Brady | Director | Purchase of securities on an exchange or from another person at price $ 14.40 per share. | 21 Nov 2025 | 3,469 | 17,481 (0%) | 0% | 14.4 | 49,962 | Common Stock, $0.50 par value |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.13 per share. | 14 Nov 2025 | 158 | 7,532 (0%) | 0% | 15.1 | 2,390 | Common Stock |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 40 | 15,725 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 345.50 per share. | 15 Oct 2025 | 6 | 15,719 (0%) | 0% | 345.5 | 2,073 | Ordinary Shares, nominal value $0.000304635 per share |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 14.94 per share. | 03 Oct 2025 | 160 | 7,373 (0%) | 0% | 14.9 | 2,390 | Common Stock |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 6,000 | 6,000 | - | - | Common Stock Option | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 345.45 per share. | 01 Oct 2025 | 1,577 | 16,003 (0%) | 0% | 345.5 | 544,775 | Ordinary Shares, nominal value $0.000304635 per share |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 345.45 per share. | 01 Oct 2025 | 315 | 15,688 (0%) | 0% | 345.5 | 108,817 | Ordinary Shares, nominal value $0.000304635 per share |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Sale of securities on an exchange or to another person at price $ 14.51 per share. | 09 Sep 2025 | 6,392 | 0 | - | 14.5 | 92,748 | Common Stock |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Other type of transaction at price $ 0.00 per share. | 09 Sep 2025 | 6,392 | 6,392 | - | 0 | Common Stock | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 05 Sep 2025 | 159 | 7,212 (0%) | 0% | 15.0 | 2,390 | Common Stock |
| SAB Biotherapeutics Inc | Lucy To | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 1,200,000 | 1,200,000 | - | - | Stock Option (right to buy) | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 14.40 per share. | 08 Aug 2025 | 166 | 7,053 (0%) | 0% | 14.4 | 2,390 | Common Stock |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 44 | 17,580 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 14.84 per share. | 11 Jul 2025 | 161 | 6,887 (0%) | 0% | 14.8 | 2,390 | Common Stock |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 13.98 per share. | 13 Jun 2025 | 171 | 6,725 (0%) | 0% | 14.0 | 2,390 | Common Stock |
| Bath & Body Works Inc | Lucy O. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 5,641 | 14,012 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Pacific Biosciences of California Inc | Lucy Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Hertz Global Holdings Inc - Ordinary Shares (New) | Lucy Clark Dougherty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 28,000 | 70,889 (0%) | 0% | 0 | Common Stock | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 14,609 | 14,609 | - | - | Restricted Stock Units | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 10,724 | 10,724 | - | - | Restricted Stock Units | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.22 per share. | 16 May 2025 | 157 | 6,553 (0%) | 0% | 15.2 | 2,390 | Common Stock |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 30,000 | 30,000 | - | - | Common Stock Option | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2025 | 1,422 | 17,535 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 13.35 per share. | 17 Apr 2025 | 179 | 6,396 (0%) | 0% | 13.4 | 2,390 | Common Stock |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 37 | 16,112 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Natural Health Trends Corp | Lucy Nduati | Director | 01 Apr 2025 | 10,370 | 10,370 | - | - | Phantom Stock | ||
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 21 Mar 2025 | 159 | 6,216 (0%) | 0% | 15.0 | 2,390 | Common Stock |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 21 Mar 2025 | 159 | 6,216 (0%) | 0% | 15.0 | 2,390 | Common Stock |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.01 per share. | 11 Mar 2025 | 3,207 | 3,207 (0%) | 0% | 15.0 | 48,137 | Common Stock |
| Sinclair Inc (Class A) | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 144,196 | 239,716 (0%) | 0% | - | Class A Common Stock | |
| Sinclair Inc (Class A) | Lucy A. Rutishauser | SVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.87 per share. | 28 Feb 2025 | 69,648 | 170,068 (0%) | 0% | 13.9 | 966,018 | Class A Common Stock |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 93,000 | 93,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 46,500 | 79,170 | - | 0 | Common Stock | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.42 per share. | 21 Feb 2025 | 155 | 6,057 (0%) | 0% | 15.4 | 2,390 | Common Stock |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.52 per share. | 24 Jan 2025 | 154 | 5,902 (0%) | 0% | 15.5 | 2,390 | Common Stock |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 37 | 16,075 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 2,957 | 32,670 | - | 1.3 | 3,965 | Common Stock |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 23,585 | 50,759 (0%) | 0% | - | Common Stock | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 23,585 | 0 | - | - | Restricted Stock Unit | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 21,552 | 21,552 | - | - | Restricted Stock Unit | |
| Fortress Biotech Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 49,383 | 61,273 (0%) | 0% | 0 | common stock, par value $0.001 | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 300.58 per share. | 15 Oct 2024 | 2,424 | 16,038 (0%) | 0% | 300.6 | 728,606 | Ordinary Shares, nominal value $0.000304635 per share |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 70,000 | 70,000 | - | - | Common Stock Option | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 9,980 | 13,306 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 5,156 | 18,462 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 3,326 | 3,326 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Hertz Global Holdings Inc - Ordinary Shares (New) | Lucy Clark Dougherty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 42,889 | 42,889 (0%) | 0% | 0 | Common Stock | |
| SAB Biotherapeutics Inc | Lucy To | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 20,000 | 20,000 | - | - | Common Stock Option | |
| Bath & Body Works Inc | Lucy O. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,844 | 8,371 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Pacific Biosciences of California Inc | Lucy Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 32,179 | 32,179 | - | - | Stock Option (right to buy) | |
| Pacific Biosciences of California Inc | Lucy Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 22,821 | 22,821 (0%) | 0% | 0 | Common Stock | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,724 | 10,724 | - | - | Restricted Stock Units | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 13,125 | 13,125 | - | - | Stock Option | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| Sinclair Inc (Class A) | Lucy A. Rutishauser | SVP & CFO | 08 Mar 2024 | 436,000 | 919,768 | - | - | Stock Appreciation Rights | ||
| Sinclair Inc (Class A) | Lucy A. Rutishauser | SVP & CFO | 08 Mar 2024 | 37,566 | 113,666 (0%) | 0% | - | Class A Common Stock | ||
| Sinclair Inc (Class A) | Lucy A. Rutishauser | SVP & CFO | 08 Mar 2024 | 18,146 | 95,520 (0%) | 0% | 13.3 | 241,523 | Class A Common Stock | |
| Columbia Fin Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 3,018 | 3,018 (0%) | 0% | 0 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 22,020 | 22,020 | - | - | Employee Stock Option (right to buy) |